Statistics for First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
Total visits
| views | |
|---|---|
| First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer | 5 |
Total visits per month
| views | |
|---|---|
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:f23a2d29-e855-412c-af0f-7eb0c925edff | 85 |
| Pegram2021FirstHuman-CCBYNCND.pdf | 55 |
| java.util.UUID:57a6d87b-e375-4223-bf8c-4373a96f5faa | 12 |
| java.util.UUID:6f03fa0a-3cb6-45fa-ae19-2b32e4712d35 | 6 |
Top country views
| views | |
|---|---|
| United States | 4 |
| South Korea | 1 |
Top city views
| views | |
|---|---|
| Bloomington | 3 |
| Gangnam-gu | 1 |
| Muncie | 1 |